Cargando…
Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin
Accumulation of amyloid-β (Aβ) peptides and amyloid plaque deposition in brain is postulated as a cause of Alzheimer’s disease (AD). The precise pathological species of Aβ remains elusive although evidence suggests soluble oligomers may be primarily responsible for neurotoxicity. Crenezumab is a hum...
Autores principales: | Ultsch, Mark, Li, Bing, Maurer, Till, Mathieu, Mary, Adolfsson, Oskar, Muhs, Andreas, Pfeifer, Andrea, Pihlgren, Maria, Bainbridge, Travis W., Reichelt, Mike, Ernst, James A., Eigenbrot, Charles, Fuh, Germaine, Atwal, Jasvinder K., Watts, Ryan J., Wang, Weiru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5171940/ https://www.ncbi.nlm.nih.gov/pubmed/27996029 http://dx.doi.org/10.1038/srep39374 |
Ejemplares similares
-
Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric Aβ
por: Meilandt, William J., et al.
Publicado: (2019) -
Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid
por: Yang, Ting, et al.
Publicado: (2019) -
Novel Phospho-Tau Monoclonal Antibody Generated Using a Liposomal Vaccine, with Enhanced Recognition of a Conformational Tauopathy Epitope
por: Theunis, Clara, et al.
Publicado: (2017) -
Anti-amyloid-β Monoclonal Antibodies as Promising Disease-Modifying Therapies in Alzheimer’s Disease: A Focus on Aducanumab, Lecanemab, Crenezumab, Gantenerumab and Solanezumab
por: Melo, V. S. D., et al.
Publicado: (2023) -
ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease
por: Cummings, Jeffrey L., et al.
Publicado: (2018)